172 related articles for article (PubMed ID: 4570039)
1. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis.
Block ER; Bennett JE
Proc Soc Exp Biol Med; 1973 Feb; 142(2):476-80. PubMed ID: 4570039
[No Abstract] [Full Text] [Related]
2. Letter: Amphotericin B and 5-fluorocytosine.
Medoff G; Kobayashi GS
J Infect Dis; 1975 Oct; 132(4):489-90. PubMed ID: 1102615
[No Abstract] [Full Text] [Related]
3. Cryptococcal meningitis treated with 5-fluorocytosine and amphotericin B.
Halkin H; Ravid M; Zulman J; Reichert N
Isr J Med Sci; 1974 Sep; 10(9):1148-52. PubMed ID: 4611967
[No Abstract] [Full Text] [Related]
4. Colonic cryptococcus infection.
Law JK; Amar JN; Kirby SD; Zetler PJ; Enns RA
Gastrointest Endosc; 2007 Mar; 65(3):525-6, discussion 526. PubMed ID: 17208240
[No Abstract] [Full Text] [Related]
5. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
6. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.
Hamilton JD; Elliott DM
J Infect Dis; 1975 Feb; 131(2):129-37. PubMed ID: 1090685
[TBL] [Abstract][Full Text] [Related]
7. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?
Viviani MA; Esposto MC; Cogliati M; Tortorano AM
J Chemother; 2003 Apr; 15(2):124-8. PubMed ID: 12797387
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
Silva EG; Paula CR; de Assis Baroni F; Gambale W
Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole.
Orni-Wasserlauf R; Izkhakov E; Siegman-Igra Y; Bash E; Polacheck I; Giladi M
Clin Infect Dis; 1999 Dec; 29(6):1592-3. PubMed ID: 10585832
[No Abstract] [Full Text] [Related]
10. In vitro and in vivo studies on synergistic antifungal activity.
Shadomy S
Contrib Microbiol Immunol; 1977; 4():147-57. PubMed ID: 342191
[No Abstract] [Full Text] [Related]
11. Combination of oral flucytosine and ketoconazole as therapy for experimental cryptococcal meningitis.
Craven PC; Graybill JR
J Infect Dis; 1984 Apr; 149(4):584-90. PubMed ID: 6327836
[TBL] [Abstract][Full Text] [Related]
12. [Amphotericin-B and 5-fluorocytosine in the treatment of cryptococcosis of the central nervous system].
Nobrega JP; Livramento JA; Spina-França A
Arq Neuropsiquiatr; 1975 Sep; 33(3):210-6. PubMed ID: 1242303
[No Abstract] [Full Text] [Related]
13. 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans.
Chin CS; Cheong YM; Wong YH
Med J Malaysia; 1989 Sep; 44(3):194-8. PubMed ID: 2696871
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.
Pereira TC; do Carmo PHF; de Menezes RT; de Oliveira HC; de Oliveira LD; Junqueira JC; Scorzoni L
Folia Microbiol (Praha); 2023 Dec; 68(6):999-1004. PubMed ID: 37950840
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
16. Current approach to the acute management of cryptococcal infections.
Powderly WG
J Infect; 2000 Jul; 41(1):18-22. PubMed ID: 11041709
[No Abstract] [Full Text] [Related]
17. Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo.
Sneller MR; Hariri A; Sorenson WG; Larsh HW
Antimicrob Agents Chemother; 1977 Sep; 12(3):390-4. PubMed ID: 334065
[TBL] [Abstract][Full Text] [Related]
18. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans.
Chen HH; Liushih RN; Hsieh WC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole.
Perfect JR; Durack DT
J Infect Dis; 1982 Sep; 146(3):429-35. PubMed ID: 6286799
[TBL] [Abstract][Full Text] [Related]
20. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
